Alpha Teknova (NASDAQ:TKNO) Share Price Breaks Below 50 Day Moving Average - Should You Sell?

Alpha Teknova logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Alpha Teknova fell below its 50-day moving average, trading at $7.77 versus the $7.87 average; it remains above its 200-day average of $5.14.
  • Analysts’ consensus is “Moderate Buy”, with an average price target of $8.75. Four analysts rate the stock Buy, one Hold, and one Sell.
  • The company reported a quarterly loss of $0.06 per share, slightly better than estimates, and revenue of $12.7 million, above expectations; it continues to report negative net income.
  • MarketBeat previews top five stocks to own in December.

Alpha Teknova, Inc. (NASDAQ:TKNO - Get Free Report) crossed below its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $7.87 and traded as low as $7.71. Alpha Teknova shares last traded at $7.77, with a volume of 420,861 shares trading hands.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Zacks Research raised Alpha Teknova to a "hold" rating in a research report on Thursday, August 6th. TD Cowen boosted their price target on shares of Alpha Teknova from $7.00 to $11.00 and gave the company a "buy" rating in a report on Tuesday, October 13th. BTIG Research upgraded shares of Alpha Teknova from a "neutral" rating to a "buy" rating and set a $8.00 price objective for the company in a research note on Tuesday, August 11th. Wall Street Zen upgraded shares of Alpha Teknova from a "hold" rating to a "buy" rating in a research note on Saturday, August 8th. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Alpha Teknova in a report on Wednesday, November 4th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $8.75.

Get Our Latest Stock Report on TKNO

Alpha Teknova Price Performance

The stock has a fifty day moving average of $7.87 and a 200-day moving average of $5.14. The company has a quick ratio of 3.48, a current ratio of 3.56 and a debt-to-equity ratio of 0.22. The firm has a market capitalization of $488.73 million, a P/E ratio of -26.79 and a beta of 0.96.

Alpha Teknova (NASDAQ:TKNO - Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The firm had revenue of $12.70 million for the quarter, compared to analyst estimates of $11.71 million. Alpha Teknova had a negative net margin of 34.76% and a negative return on equity of 24.95%. Equities analysts predict that Alpha Teknova, Inc. will post -0.27 EPS for the current fiscal year.

Hedge Funds Weigh In On Alpha Teknova

Large investors have recently modified their holdings of the stock. BlackRock Inc. bought a new stake in shares of Alpha Teknova during the 2nd quarter valued at $4,997,000. Bank of America Corp DE acquired a new position in shares of Alpha Teknova in the 2nd quarter valued at $1,453,000. Bank of New York Mellon Corp acquired a new position in shares of Alpha Teknova in the 2nd quarter valued at $604,000. Empowered Funds LLC bought a new position in shares of Alpha Teknova in the 3rd quarter worth $656,000. Finally, GSA Capital Partners LLP bought a new position in shares of Alpha Teknova in the 2nd quarter worth $303,000. 13.81% of the stock is currently owned by institutional investors and hedge funds.

Alpha Teknova Company Profile

(Get Free Report)

Alpha Teknova, Inc. develops and manufactures reagents used in life science research and the development and production of biopharmaceuticals and diagnostic products. Its offerings include cell culture media, buffers, molecular biology reagents, proteins and other laboratory materials. The company provides both catalog products and custom reagent development and manufacturing services. Its customers include biotechnology and pharmaceutical companies, diagnostic developers, academic institutions and research laboratories.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Alpha Teknova Right Now?

Before you consider Alpha Teknova, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Teknova wasn't on the list.

While Alpha Teknova currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines